Company
Headquarters: Santa Clara, CA, United States
Employees: 352
CEO: Ms. Laura A. Francis
$692.8 Million
USD as of Jan. 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $138.9 M |
| EBITDA | $-41,503,000 |
| Gross Profit TTM | $109.4 M |
| Profit Margin | -31.20% |
| Operating Margin | -32.18% |
| Quarterly Revenue Growth | 21.60% |
SI-BONE, Inc. has the following listings and related stock indices.
Stock: NASDAQ: SIBN wb_incandescent
Stock: FSX: 2K3 wb_incandescent
Stock: Munich: 2K3 wb_incandescent